Department of Oncology, Centre of Experimental and Clinical Oncology, Florence University, Florence, Italy.
Anticancer Res. 2010 Dec;30(12):5169-73.
The activity of sunitinib, a multitargeted tyrosine kinase inhibitor with antiangiogenic and antitumor activities, has been explored in several solid malignancies such as breast, lung, prostate and pancreatic cancer. Currently it is approved for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Non-small cell lung cancer usually presents at an advanced or metastatic stage at diagnosis. Treatment options are limited for this disease, therefore symptom palliation and patient's quality of life are primary objectives of therapy.
We describe the case of a patient (male, 67 years old) with heavily pre-treated metastatic non-small cell lung carcinoma who received sunitinib according to the following 3-week schedule: 50 mg daily for 2 weeks followed by a 1-week rest. The patient completed six months of therapy achieving a major disease response without high-grade toxicities.
In this case, sunitinib shows promising single-agent activity in pretreated non-small cell lung cancer, with a good toxicity profile and flexible administration schedule.
舒尼替尼是一种具有抗血管生成和抗肿瘤活性的多靶点酪氨酸激酶抑制剂，已在多种实体恶性肿瘤中进行了研究，如乳腺癌、肺癌、前列腺癌和胰腺癌。目前，它被批准用于治疗转移性肾细胞癌和胃肠道间质瘤。非小细胞肺癌通常在诊断时处于晚期或转移阶段。对于这种疾病，治疗选择有限，因此症状缓解和患者的生活质量是治疗的主要目标。
我们描述了一名患有广泛预处理转移性非小细胞肺癌的患者（男性，67 岁）接受舒尼替尼治疗的情况，方案为：每日 50mg，连续服用 2 周，然后休息 1 周。该患者完成了 6 个月的治疗，达到了主要疾病缓解，且无高级别毒性。
在本例中，舒尼替尼在预处理的非小细胞肺癌中显示出有前景的单药活性，具有良好的毒性特征和灵活的给药方案。
